×
QQQ   283.80 (+0.09%)
AAPL   139.23 (+1.30%)
MSFT   260.26 (+1.47%)
META   163.94 (+2.03%)
GOOGL   2,234.03 (-0.27%)
AMZN   108.92 (+1.42%)
TSLA   685.47 (-1.79%)
NVDA   155.42 (-2.75%)
NIO   21.86 (-2.24%)
BABA   116.03 (-0.63%)
AMD   77.99 (-3.45%)
MU   56.02 (-3.18%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.65 (-0.28%)
AMC   13.65 (+2.02%)
PFE   50.94 (+0.55%)
PYPL   71.47 (-0.49%)
NFLX   178.36 (-0.69%)
QQQ   283.80 (+0.09%)
AAPL   139.23 (+1.30%)
MSFT   260.26 (+1.47%)
META   163.94 (+2.03%)
GOOGL   2,234.03 (-0.27%)
AMZN   108.92 (+1.42%)
TSLA   685.47 (-1.79%)
NVDA   155.42 (-2.75%)
NIO   21.86 (-2.24%)
BABA   116.03 (-0.63%)
AMD   77.99 (-3.45%)
MU   56.02 (-3.18%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.65 (-0.28%)
AMC   13.65 (+2.02%)
PFE   50.94 (+0.55%)
PYPL   71.47 (-0.49%)
NFLX   178.36 (-0.69%)
QQQ   283.80 (+0.09%)
AAPL   139.23 (+1.30%)
MSFT   260.26 (+1.47%)
META   163.94 (+2.03%)
GOOGL   2,234.03 (-0.27%)
AMZN   108.92 (+1.42%)
TSLA   685.47 (-1.79%)
NVDA   155.42 (-2.75%)
NIO   21.86 (-2.24%)
BABA   116.03 (-0.63%)
AMD   77.99 (-3.45%)
MU   56.02 (-3.18%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.65 (-0.28%)
AMC   13.65 (+2.02%)
PFE   50.94 (+0.55%)
PYPL   71.47 (-0.49%)
NFLX   178.36 (-0.69%)
QQQ   283.80 (+0.09%)
AAPL   139.23 (+1.30%)
MSFT   260.26 (+1.47%)
META   163.94 (+2.03%)
GOOGL   2,234.03 (-0.27%)
AMZN   108.92 (+1.42%)
TSLA   685.47 (-1.79%)
NVDA   155.42 (-2.75%)
NIO   21.86 (-2.24%)
BABA   116.03 (-0.63%)
AMD   77.99 (-3.45%)
MU   56.02 (-3.18%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.65 (-0.28%)
AMC   13.65 (+2.02%)
PFE   50.94 (+0.55%)
PYPL   71.47 (-0.49%)
NFLX   178.36 (-0.69%)
LON:GENI

GENinCode Share Forecast, Price & News

Add
Compare
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
54,271 shs
Average Volume
71,738 shs
Market Capitalization
£18.21 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Receive GENI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GENinCode and its competitors with MarketBeat's FREE daily newsletter.

GENI Stock Forecast (MarketRank)

Overall MarketRank

0.00 out of 5 stars

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

About GENinCode

GENinCode Plc engages in the development and commercialization of clinical genetic tests to provide predictive analysis of risk to a patient's health based on their genes in the United Kingdom and internationally. Its predictive technology provides patients and physicians with preventative care and treatment strategies. The company's molecular tests combine clinical algorithms and artificial intelligence to provide advanced patient risk assessment to predict disease onset. Its tests include Cardio inCode, a patented genetic test to help user to adopt cardiovascular prevention steps; Lipid inCode, a genetic diagnostic test, which analyzes the seven genes associated with familial hypercholesterolemia; SUDD inCode, a genetic test to diagnose the cause of sudden cardiac death and familial heart disease; Thrombo inCode, a genetic test that analyzes 12 genetic variants related to hereditary thrombophilia and the risk of thrombosis; and Thrombo inCode Reproductive Health, a genetic test that offers information related to risk of thrombophilia and associated risks for future pregnancies. GENinCode Plc was incorporated in 2018 and is based in Oxford, the United Kingdom.

GENI Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com

Industry, Sector and Symbol

Industry
Diagnostics & Research
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£1.15 million
Book Value
GBX 14.30 per share

Miscellaneous

Free Float
N/A
Market Cap
£18.21 million
Optionable
Optionable
Beta
N/A














GENinCode Frequently Asked Questions

Who are GENinCode's key executives?

GENinCode's management team includes the following people:
  • Mr. Matthew Heaton Walls, Co-Founder, CEO & Director (Age 58, Pay $259.07k)
  • Mr. Jordi Puig Gilberte, Co-Founder, COO & Director
  • Mr. Paul Andrew Peter Foulger, CFO, Company Sec. & Director (Age 52, Pay $126.42k)

What is GENinCode's stock symbol?

GENinCode trades on the London Stock Exchange (LON) under the ticker symbol "GENI."

How do I buy shares of GENinCode?

Shares of GENI and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

How much money does GENinCode make?

GENinCode (LON:GENI) has a market capitalization of £0.00 and generates £1.15 million in revenue each year.

How can I contact GENinCode?

The official website for GENinCode is www.genincode.com. The company can be reached via phone at 44 1865 955 847.

This page (LON:GENI) was last updated on 6/29/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.